- Monosubstituted and polysubstituted functional group aromatic ketone compounds, and preparation method and photopolymerization initiator thereof
-
The invention belongs to the field of radiation curing new materials, and relates to an aromatic ketone compound, in particular to a monosubstituted or polysubstituted polyfunctional group aromatic ketone compound, a preparation method thereof and a photopolymerization composition containing an ethylenically unsaturated compound system, which takes the compound as an effective component. The invention provides monosubstituted and polysubstituted polyfunctional group aromatic ketone compounds. The polyfunctional group aromatic ketone compounds have a general formula structure as shown in (I). The invention also discloses a preparation method and an application of the polyfunctional aromatic ketone compound. According to the invention, industrial-grade raw materials which are low in cost and easy to obtain are used as a starting point to prepare the monosubstituted or polysubstituted functionalized aromatic ketone compound in a breakthrough way, and the compound is applied to a photoinitiator in radiation curing, so that the problems of toxicity and VOCs pollution of the photoinitiator are solved, and the economic competitiveness of the photoinitiator is strived; the overall cost is reduced, and the photo-initiation efficiency is improved.
- -
-
Paragraph 0059-0061
(2022/01/08)
-
- NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB
-
The present invention concerns a process for the preparation of firocoxib, i.e. 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)-furan-2-one, comprising steps (a)-(g), wherein the process provides for step (d) of the reaction of a new intermediate, i.e. 2-methyl-1-[4-(methylsulfanyl)phenyl]-1-oxopropan-2-yl (acetyloxy)acetate (compound VII) in the same organic solvent of step (a) in the presence of a catalyst and a phase transfer catalyst solution in the same organic solvent with hydrogen peroxide.
- -
-
Page/Page column 5; 7; 8; 12; 13; 18
(2018/11/10)
-
- PROCESS FOR THE PREPARATION OF ALPHA-FUNCTIONALIZED KETONES
-
The present invention refers to a process for the preparation of an α-functionalized ketone, an α-functionalized ketone obtained by said process, a photopolymerizable composition comprising the α-functionalized ketone and at least one photopolymerizable unsaturated compound, a method of preparing an article, an article obtained by said method, as well as the use of the α-functionalized ketone or the photopolymerizable composition as photoinitiator.
- -
-
Page/Page column 49
(2018/11/22)
-
- An improved and practical synthesis of 5,5-dimethyl-3-(2-propoxy)-4-(4-methanesulfonylphenyl)-2-(5H)-furanone (DFP - A selective inhibitor of cyclooxygenase-2)
-
DFP, a highly selective and potent COX-2 inhibitor, has been synthesized by a modified approach. Three modifications of the existing method enabled us to prepare DFP in good quantity.
- Padakanti, Srinivas,Pal, Manojit,Yeleswarapu, Koteswar Rao
-
p. 7915 - 7920
(2007/10/03)
-
- (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES WITH OXYGEN LINK AS COX-2 INHIBITORS
-
The invention encompasses the novel compound of Formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising co
- -
-
-
- Diaryl-2-(5H)-furanones as Cox-2 inhibitors
-
The invention encompasses the novel compound of Formula (I) as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula (I). The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula (I).
- -
-
-
- (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
-
The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
- -
-
-
- (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors
-
The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising comp
- -
-
-
- ALKYLATED STYRENES AS PRODRUGS TO COX-2 INHIBITORS
-
The invention encompasses the novel compound of formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of formula (I).
- -
-
-
- A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors
-
By inserting an oxygen link between the 3-fluorophenyl and the lactone ring of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methanesulfonylphenyl)-2(5H)-furanone 1 (DFU), analogs with enhanced in vitro COX-2 inhibitory potency as well as in vivo potency in models of inflammation were obtained.
- Li, Chun-Sing,Black, W. Cameron,Brideau, Christine,Chan, Chi Chung,Charleson, Stella,Cromlish, Wanda A.,Claveau, David,Yves Gauthier, Jacques,Gordon, Robert,Greig, Gillian,Grimm, Erich,Guay, Jocelyne,Lau, Cheuk K.,Riendeau, Denis,Therien, Michel,Visco, Denise M.,Wong, Elizabeth,Xu, Lijing,Prasit, Petpiboon
-
p. 3181 - 3186
(2007/10/03)
-
- SAR in the alkoxy lactone series: The discovery of DFP, a potent and orally active COX-2 inhibitor
-
Extensive SAR has been established in the alkoxy lactone series and this has lead to the discovery of DFP (5,5-dimethyl-3-(2-propoxy)-4- methanesulfonylphenyl)-2(5H)-furanone), a potent COX-2 inhibitor exhibiting in vivo efficacy in all models studied.
- Leblanc,Roy,Boyce,Brideau,Chan,Charleson,Gordon,Grimm,Guay,Leger,Li,Riendeau,Visco,Wang,Webb,Xu,Prasit
-
p. 2207 - 2212
(2007/10/03)
-
- (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
-
The invention encompasses the novel compound of Formula A that is useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula A.
- -
-
-
- Phenyl heterocycles as cox-2 inhibitors
-
The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
- -
-
-
- Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
-
The present invention provides a method of treating a neurodegenerative disease and in particular Alzheimers disease which comprises administering to a human in need thereof a therapeutically effective amount of a non-steroid COX-II inhibitor. Although a wide range of COX-II inhibitors may be employed but it is preferred to employ compounds of the Formula I: STR1
- -
-
-
- Alkylated styrenes as prodrugs to COX-2 inhibitors
-
The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
- -
-
-
- Method of preventing bone loss
-
The invention encompasses a method of inhibiting bone resorption in patients in need of such inhibition to a degree sufficient to halt or retard loss of bone mass, reduce fractures, improve bone repair and prevent or treat osteoporosis comprising: the administration of a non-toxic therapeutically effective amount of a selective cyclooxygenase-2 inhibitor such as the compounds of formula I. STR1 The invention also encompasses certain pharmaceutical compositions for the purposes described above.
- -
-
-
- 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to COX-2 inhibitors
-
The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
- -
-
-